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Abstract
The utility of cells cultured from the mitral valve as models of myxomatous diseases needs
to be properly validated. In this study valve interstitial cells (VICs) and valve endothelial cells
(VECs) were cultured from normal and diseased canine mitral valves in 2% (v/v) or 10%
FBS media, in the presence of TGFβ1, 2 and 3, the TGFβ RI kinase inhibitor SB431542 and
TGFβ neutralising antibodies, 5HT and the 5HT2RB antagonist LY272015. Cultures were
examined by morphology, transcriptomic profiling, protein expression of the cell specific
markers αSMA and SM22α (VICs), and CD31 (VECs), deposition of proteoglycans (PG),
the PG versican, and the TGFβs themselves. VECs derived from normal valves were CD31
+/αSMA-, but those from diseased valves were αSMA+, indicating endothelial-to-mesen-
chymal (EndoMT) transition had occurred. The TGFβs induced EndoMT in normal VECs,
and this was abolished by SB431542, with significant changes in αSMA, CD31 and HAS2
expression (P<0.05). Normal VICs cultured in 10% FBS media were αSMA+ (activated myo-
fibroblast (disease) phenotype), but were αSMA- when grown in 2% FBS. VICs from dis-
eased dogs were αSMA+ in 2% FBS (retention of the activated myofibroblast disease
phenotype), with significantly increased TGFβ1 expression (P<0.05) compared to normal
cells. Treatment of normal and diseased VICs with the TGFβs significantly increased
expression of αSMA, SM22α, versican, the TGFβs themselves, and deposition of PGs
(P<0.05), with TGFβ1 being the most potent activator. These effects were either abolished
or markedly reduced by SB431542 and a pan-TGFβ neutralizing antibody (P<0.05).
SB431542 also markedly reduced αSMA expression in VICs from diseased valves, but 5HT
and LY272015 had no effect on VIC phenotype. Transcriptomic profiling identified clear dif-
ferences in gene expression for the different conditions and treatments that partially
matched that seen in native diseased valve tissue, including changes in expression of
ACTA2 (αSMA), 5HTR2B, TAGLN (SM22α) and MYH10 (SMemb), gene ontology terms
and canonical signalling pathways. Normal and diseased VICs and normal VECs from
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canine mitral valves can be successfully grown in culture with retention of phenotype, which
can be manipulated using TGFβ1 and the TGFβ RI kinase inhibitor SB431542. This opti-
mized cell system can now be used to model MMVD to elucidate disease mechanisms and
identify key regulators of disease progression.
Introduction
Myxomatous mitral valve degeneration (MMVD) is the single most common acquired cardio-
vascular disease of the dog, and an important pathological component of a range of valvulopa-
thies in humans, including Barlow’s Disease and Fibroelastic Deficiency, making the dog a
potentially useful naturally-occurring large animal model for acquired human mitral valvulo-
pathies [1–4]. Key pathological changes of myxomatous degeneration in both species involve
the extracellular matrix (ECM) with progressive loss and disorganization of collagen bundles
and elastin fibres and the accumulation of proteoglycans (PGs) and glycosaminoglycans
(GAGs) [5–7].
The pathogenesis of MMVD is only partially understood. Loss of mitral valve endothelial
cells (VECs), endothelial-to-mesenchymal transition (EndoMT) and transition of normally
quiescent valvular interstitial cells (qVICs) into activated myofibroblasts (aVICs) likely con-
tribute to the ECM changes seen [1, 8–12]. Changes in a number of signalling pathways have
been reported including the TGFβ/BMP super-family, 5-hydroxytryptamine (5HT, serotonin),
angiotensin and Wnt/β-catenin [13–19]. EndoMT has been shown to be activated in canine
MMVD and a sheep model where VECs lose expression of CD31 (PECAM1, platelet and
endothelial cell adhesion molecule 1) and CDH5 (cadherin 5), and gain αSMA expression, and
transcriptomic data would suggest this also occurs in human MMVD [12]. αSMA is also a
marker for activated myofibroblasts. Diseased canine valves have increasing numbers of
αSMA+ myofibroblasts and TGFβ1 mediates αSMA+ myofibroblast transformation in cul-
tured VICs [11, 20–22].
TGFβ signalling appears to be the prominent pathway implicated in MMVD [14, 21, 23,
24]. Canonical SMAD-dependent TGFβ pathway activation and up-regulation found in
human MMVD possibly reflects end-stage fibrosis, but transcriptomic evidence from the dog
suggests involvement of non-canonical TGFβ signaling pathways, and this may well be the
case in the early non-fibrotic stage of human MMVD [14, 16–18, 25–29]. A role for 5HT sig-
naling in MMVD is also suspected [30, 31]. With TGFβ, 5HT may be important in ECM regu-
lation, and while consistent up-regulation of the 5HTR2A and 5HTR2B 5HT receptor genes in
MMVD has been reported, 5HT itself does not increase expression of αSMA in normal VICs
[14, 16, 19, 23, 30, 31]. Mechanical stimulation of tissue engineered valves (human) does
induce 5HTR2A, 5HTR2B and ACTA2 (αSMA) gene expression and these effects can be
blocked by the 5HTR2B antagonist LY272015 [31].
Culture of canine mitral valve cells has been reported, but none are reliable in vitro models
of MMVD due to spontaneous increased expression of αSMA in both VICs and VECs when
cultured in standard culture media containing 10%FBS v/v [32–34]. In conventional monocul-
tures with 10% FBS, normal VECs spontaneously undergo EndoMT and qVICs have an
αSMA+ activated myofibroblastic (aVIC) phenotype, which hampers comparison between
normal and diseased states, and this clearly limits options for functional and mechanistic stud-
ies of pathogenesis using cultured cells [33]. However, low serum media have been shown to
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maintain the quiescent phenotype of VICs from human aortic valves and prevent EndoMT in
VECs from canine mitral valves [33, 35, 36].
The aims of this study, therefore, were to examine cell culture models of MMVD using
canine-derived qVICs, aVICs and VECs from normal and diseased mitral valves, under low-
serum conditions, identify the appropriate TGFβ factors necessary for disease phenotype
induction, and examine the effects of neutralizing TGFβ antibodies, the TGFβ receptor inhibi-
tor SB431542 and the 5HTR2B antagonist LY272015 on cell phenotype, using a combination
of morphological assessment, protein immunoblotting, immunohistochemistry, PCR and
transcriptomic profiling.
Materials & methods
Cell isolation and culture
Cells were collected from healthy young adult dogs (n = 6) and diseased middle-aged dogs
(n = 7) of various breeds. The ubiquity of MMVD in the dog makes it problematic to identify
age-matched normal controls. Valves were collected with full owner consent, no dogs were
euthanized for the purpose of this study. The Royal (Dick) School of Veterinary Studies, Veter-
inary Ethics Research Committee (Institutional Care and Use Committee) approved this
study). Resected valves were graded normal (grade 0) or diseased (grade 1–4) using the stan-
dard Whitney classification and graded independently by two observers [37]. VECs were iso-
lated using collagenase digestion as previously reported [33]. Cells were cultivated using
standard tissue culture techniques and not used beyond passage 8. A low serum (2% v/v FBS),
with added FGF-2 (10ng/ml) and insulin (50ng/ml) DMEM medium (DMEM Low FBS
(DLF); Gibco) was used for VICs, and the effect initially compared with a high serum (10% v/v
FBS) DMEM medium without FGF-2 and insulin (DMEM High FBS (DH)) [33, 35]. For
VECs, canine endothelial cell growth medium (CEM) was used (Cell Applications Inc.). VECs
from diseased valves proved difficult to isolate and grow in sufficient numbers and were not
included in this study. For TGFβ1, 2 or 3 (Gibco Life Sciences) and the TGFβRI antagonist
SB431542, control vehicle was 4mM HCl, 0.1% w/v bovine serum albumin (BSA, Sigma-
Aldrich) and diemethylsulfoxide (DMSO) respectively. Pan TGFβ1, 2, 3 and TGFβ1, TGFβ2
and TGFβ3 neutralizing antibodies (R&D Systems) were used at 1 or 10μg/ml. Six-well plates
were seeded at 1.5x105 cells/well. 96 well plates used for CellTitre-Glo luminescent cell viability
assays (Promega) were seeded at 3x103 cells/well, and at 4x105 for transcriptomic profiling.
Harvested cell pellets had RNA and protein extracted as outlined below and supernatants were
stored for proteoglycan assays and ELISAs. All experiments were carried out with three techni-
cal replicates.
The effects of TGFβ1, 2 or 3 (0.1-10ng/ml) and SB431542 (10μM; Sigma Aldrich,) on VECs
and qVICs and aVICs, and the effects of 5HT (100nM), neutralising anti-TGFβ antibodies
(1μM) and LY272015 (1μM and 100nM) (Santa Cruz Biotechnology, USA) on qVICs and
aVICs, were assessed and details of marker antibodies used are shown in S1 Table.
Molecular biology analysis
RNA was isolated using the RNeasy mini kit (Qiagen) with cell homogenization using QIAsh-
redders and DNAse I treatment. Quantity and quality of RNA was assessed by NanoDrop
ND1000 (Thermo Scientific). For TGFβ RT-PCR experiments reverse transcription with
oligo-dT primers was performed on 2μg of total RNA using Omniscript reverse transcriptase
(Qiagen) at 37˚C for 1h, before PCR with primers of interest using HotStarTaq DNA polymer-
ase (Qiagen). Products were separated on 2% agarose gel and PCR product band intensities
were quantified using GelDoc XR (BioRad).
Cell culture myxomatous mitral valve disease
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For 5HT experiments cDNA synthesis was performed with Superscript III kit (Invitrogen).
The Takyon 2X low Rox SYBR green mastermix dTTP blue (Eurogentec) was used for quanti-
tative PCR (qPCR). qPCR was performed on the MxPro MX3000p Stratagene (Agilent Tech-
nologies). Results were analysed using MxPro version 4.1 and the relative expression
calculated using ΔΔCt method with normalisation to the geomean of the reference genes
MRPS25, GAPDH and RPL32. Primers were designed using Primer 3 v.0.4.0 (http://bioinfo.
ut.ee/primer3-0.4.0/) and nucleotide sequences obtained from the NCBI Gene Bank (https://
www.ncbi.nlm.nih.gov/genbank/) or Ensembl databases (http://www.ensembl.org) as previ-
ously reported (Table 1) (Liu et al, 2015). For microarray experiments (n = 3) qVICs were
treated with 5ng/mL TGFβ1 and DMSO (Gibco Life Sciences, PHG9204) for 72 hours. aVICs
were treated with 10μM SB431542 and 4mM HCL, 0.1% (w/v) BSA (Sigma-Aldrich, S4317)
for 96 hours. The Affymetrix GeneChip Canine Gene 1.1 ST Array plate was used for tran-
scriptomic profiling. Affymetrix transcriptome analysis console (version 3.1.0.5) was used to
perform paired or unpaired one-way analysis of variance (ANOVA). Differentially expressed
gene lists were created using the following criteria: P-value <0.05, log 2 signal intensity >3.5
and fold change of>1.5 or<-1.5. Gene enrichment analysis used Database for Annotation,
Visualisation and Integrated Discovery (DAVID; http://www.david.ncifcrf.gov) and Ingenuity
Pathway Analysis (IPA; Qiagen, Germany). DAVID predicts the biological processes that are
associated with the genes in the list using the gene ontology (GO) terms. Gene lists deriving
from differential expression analysis were uploaded to DAVID for analysis, using Canis famil-
iaris as the background. IPA identified canonical pathways, upstream regulators, disease and
biological functions. Gene list comparisons used the INDEX function of Microsoft Excel.
Protein immunoblotting
For protein immunoblotting (Western blotting, WB) cells were lysed in buffer (7M urea, 0.1M
DTT, 0.05% (v/v) Triton X-100, 25mM NaCl, 20mM HEPES, pH 7.6) and protein quantified
using the Quick Start Bradford assay (Bio-Rad). 30μg of protein lysates were electrophoresed
and blotted onto Hybond ECL nitrocellulose membranes (GE Healthcare) and subjected to
standard immunoprotocols with primary and secondary antibodies. Bands were visualized by
chemiluminescence (ECL Western Blotting Detection Reagents, GE Healthcare, Cat No.
RPN2209) using autoradiography film (GE Healthcare), and quantified (ImageJ) (NIH) as a
percentage compared to β-actin.
Cells fixed in 4% (v/v) paraformaldehyde and permeabilized with 0.3% (v/v) Triton X-100
were stained using the antibodies listed in Table 1, with DAPI as nuclear stain (Life Technolo-
gies). Cell morphology was qualitatively assessed by light and fluorescent microscopy and
images captured using a Zeiss Axiovert 40 CFL inverted microscope linked to AxioVision
software.
Enzyme-Linked Imunosorbent Assay (ELISA)
Culture supernatants (at 72hrs) were examined using human TGFβ1 (100% homology),
mouse/rat/canine/porcine TGFβ2 (Quantikine ELISA), human TGFβ3 (98% homology),
canine tumour necrosis factor (TNF) and recombinant canine IFNγ (DuoSet ELISA, R&D Sys-
tems, U.S.A.). TGFβ1 was also assayed at 120hrs. Microplates were read at 450nm using a Per-
kin Elmer Victor plate-reader. Proteoglycans were detected using a sulphated
glycosaminoglycan quantification kit (AMS Biotechnology Ltd) and readings were taken at
515nm. For these experiments values were normalised to total cellular protein (Quick Start
Bradford protein assay; Bio-Rad). Values from WB analyses, proteoglycan assays, ELISAs and
gene expression were analysed using Student’s t-test.
Cell culture myxomatous mitral valve disease
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Results
Initially, the effects of TGFβ1 on canine VEC phenotype were assessed. VECs (n = 4) were
grown in CEM and were morphologically normal (cobblestone monolayers with contact inhi-
bition) and αSMA-, unlike those grown in conventional high serum DMEM medium, which
underwent EndoMT and transformed into activated myofibroblasts (αSMA+/CD31-).
TGFβ1-treated normal VECs grown in CEM also transformed into myofibroblast-like cells
with larger central bodies and failed to form compact and confluent cobblestone monolayers.
There was a dose-dependent significant (P<0.05) up-regulation of αSMA and hyaluronic acid
synthase-2 (HAS-2), and down-regulation of CD31 protein, indicative of EndoMT (Fig 1A
and 1B). SB431542 (n = 3) significantly inhibited (P<0.05) TGFβ1-induced EndoMT (Fig 1C
and 1D). TGFβ2 and 3 had similar effects over the same dose range.
We then investigated the effects of DLF and DH media (low and high serum respectively)
on canine VIC phenotype. DLF media was superior to DH media in preventing myofibroblast
activation and maintaining VIC quiescence. DLF qVICs were less adherent, more elongated
and spindle shaped, had smaller central bodies (Fig 2A) and markedly less αSMA expression
(Fig 2B). Cells formed into proliferative clusters at 0.1ng/ml TGFβ1 and differentiated into
non-proliferative large myofibroblasts at higher concentrations (e.g. 10ng/ml), with fewer via-
ble cells observed.
Since DLF media maintained the quiescent state in normal VICs, we assessed whether
TGFβ1 treatment of these cells could induce EndoMT. TGFβ1-treated (n = 4) qVICs grown in
DLF medium differentiated into aVICs with significantly increased (P<0.05) expression of
αSMA and SM22-α (Fig 2C–2E), and treatment with TGFβ 2 and 3 had the same effect.
TGFβ2 and TGFβ3 induced secretion of TGFβ1 by qVICs, while TGFβ1 increased secretion of
TGFβ2. On the basis of these results all subsequent VIC experiments were conducted using
DLF medium only.
The phenotype of aVICs cultured from diseased valves was compared to qVICs from nor-
mal valves. aVICs had morphological features and increased αSMA typical of activated
Table 1. Primer sequences used for RT-PCR (TGFβ) and qPCR (5HT).
Gene of Interest Primer sequence PCR Product
TGFβ experiments
ACTA2
(αSMA)
FP 5’GGGGATGGGACAAAAGGACA 3’
RP 5’GCCACGTAGCAGAGCTTCTCCTTGA3’
525bp
TAGLN
(SM22)
FP 5’AAGAACGGCGTGATTCTGAG3’
RP 5’CGGTAGTGCCCATCATTCTT3’
269bp
MYH10
(SMemb)
FP 5’AGAAGCGAGCTGGAAAACTG3’
RP 5’TCTTGCTCTGTCCGATTCTG3’
252bp
VIM
(Vimentin)
FP 5’GGAGCAGCAGAACAAGATCC3’
RP 5’AGACGTGCCAAAGAAGCATT3’
282bp
GAPDH FP 5’CATCAACGGGAAGTCCATCT3’
RP 5’GTGGAAGCAGGGATGATGTT3’
428bp
5HT experiments
ACTA2
(αSMA)
FP 5’CGGCTACTCCTTTGTGACG3’
RP 5'CGTGGCCATCTCGTTCTC3'
100bp
TAGLN
(SM22)
FP 5’GACATGTTCCAGACCGTCGA3’
RP 5’CAATGACGTGCTTTCCCTCC3’
199bp
MYH10
(SMemb)
FP 5’AGAAGCGAGCTGGAAAACTG3’
RP 5’TCTTGCTCTGTCCGATTCTG3’
252bp
GAPDH FP 5'GGGAAGATGTGGCGTGAC3'
RP 5'GAAGGCCATGCCAGTGAG3'
123bp
https://doi.org/10.1371/journal.pone.0221126.t001
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myofibroblasts (Fig 3A and 3B). They also had significantly heightened gene expression for
ACTA2 (+40.7 fold change), TAGLN (+4.3) and MYH10 (+4) compared to qVICs. Baseline
TGFβ1 secretion (n = 3) was higher in aVICs compared to qVICs, but the difference achieved
significance (P<0.05) only after 120hrs in culture (Fig 3C). There was no difference in TGFβ2
and 3 or TNF expression, and all were expressed at low levels. IFNγ was below the detection
level of the assay in both qVICs and aVICs. Addition of SB431542 reduced TGFβ1 secretion in
both qVICs and aVICS, whether in the presence or absence of exogenous TGFβ1. The addition
of TGFβ1 markedly up-regulated expression of αSMA and this was reversed by SB431542.
The effects of Inhibition of TGFβ1 signalling on VIC phenotype were then assessed.
SB431542 (10μM) prevented or reversed TGFβ1-induced myofibroblast activation in both
qVICs treated with TGFβ1 (n = 4) and aVICs (n = 4) (Fig 4A and 4B). The same effect with
SB431542 was noted in aVICs that were not treated with TGFβ1. The pan-TGFβ antibody
(n = 3), but not specific neutralizing TGFβ antibodies, reduced αSMA expression (Fig 4C) and
PG deposition by aVICs, although all neutralizing antibodies could inhibit PG secretion.
TGFβ2 and TGFβ3 induced secretion of TGFβ1 by VICs, while TGFβ1 upregulated TGFβ2.
TGFβ3 levels were below the range of detection. There was significantly greater (P<0.05)
deposition of PG by aVICs compared to qVICs under all conditions (Fig 4D). TGFβ1
increased PG expression in both qVICs and aVICs (n = 3), achieving significance in aVICs,
and was inhibited by SB431542.
5HT, alongside TGFβ1, has been reported as a possible factor responsible for the develop-
ment for MMVD, and we therefore tested the impact of 5HT in our culture system. 5HT-treat-
ment of qVICs (n = 3) had no significant effect on expression of ACTA2 (αSMA), 5HTR2B,
TAGLN or MYH10 mRNA and there were no discernible changes in cell morphology or PG
Fig 1. Normal valve endothelial cells (VEC). (A) Representative protein-immunoblot of normal VECs treated with 0, 0.1, 1, 5 and 10ng/ml TGFβ1 for 5 days
(n = 4) illustrating expression of αSMA, HAS-2 and CD31. (B) Quantified expression of αSMA in (A) relative to β-actin. (C) Representative protein immunoblot
illustrating effects of SB431542 on αSMA and CD31 expression. (D) Quantified expression of αSMA in (C) relative to β-actin. Statistical analysis was performed
with Student’s t-test. �, ��, ��� P<0.05, 0.01, 0.001 respectively.
https://doi.org/10.1371/journal.pone.0221126.g001
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synthesis. LY272015 treatment (n = 3) of diseased cells at both 100nM and 1μM did not reduce
expression of ACTA2, 5HTR2B, TAGLN or MYH10 or PG secretion, but unexpectedly both
doses significantly increased expression of 5HTR2B, and 1μM also increased expression of
TAGLN. There was no effect of LY272015 on the same gene expression profile in normal cells.
Transcriptomic profiling of qVICs treated with TGFβ1 and aVICs treated with SB431542
was performed to assess the genome-wide consequences of treatment. RT-qPCR was used to
validate the microarray and results were generally in agreement except for 5HTR2B and
BMPER in the aVICs/qVICs comparison (S2 Table). Principal component analysis (PCA) of
the transcriptomic profiles identified TGFβ1 treated qVICs and untreated aVICs clustering
the furthest apart from all other samples. aVICs treated with SB431542 shifted towards the
qVIC cluster. Differential gene expression analyses comparing qVICs, qVICs treated with
TGFβ1, aVICs, and aVICs treated with SB431542 are shown as volcano plots in Fig 5. Differen-
tially expressed genes (DEGs) were identified by comparing different data sets as follows;
qVICs vs aVICs, 902 DEGs (406 down-regulated and 496 up-regulated); TGFβ1-treated qVICs
vs vehicle treated qVICs, 275 DEGs (144 down, 131 up); SB431542-treated aVICs vs vehicle
treated aVICs, 236 DEGs (115 down 121 up); TGFβ1-treated qVICs vs aVICs, 832 DEGs (490
down, 342up). 102 genes were increased in both TGFβ1-treated qVICs (induced-disease) and
Fig 2. Quiescent valve interstitial cells (VIC) activated by TGFβ1. (A) Representative photomicrographs comparing morphology of normal VICs cultured in 2%
(v/v) serum DLF and 10% (v/v) serum DH. Scale bar = 50μM. (B) Comparison of the expression of αSMA in low (DLF) and high serum (DH) conditions and in the
presence of 0.1, 1, 5 or 10ng/ml TGFβ1. (C) Representative immunofluorescent photomicrographs of increased αSMA (green) expression in normal VICs in DLF
(x20 magnification control left panel) treated with 10ng/ml TGFβ (x20 and x40 magnification centre and right panel respectively); blue DAPI staining showing cell
nuclei. (D) Protein immunoblot for αSMA, SM22α and versican in DLF. (E) Representative RT-PCR for αSMA, SM22α, SMemb and vimentin (Vim) (gene specific
primers multiplexed PCR with GAPDH housekeeping gene primers) in normal VICs untreated (0ng/ml) or treated (10ng/ml) with TGFβ1 in DLF. (F)
Quantification of staining intensities relative to β-actin for αSMA, SM22α and versican respectively in normal VICs (n = 4) in DLF. Statistical analysis was
performed with Student’s t-test. �, ��, ��� P<0.05, 0.01, 0.001 respectively.
https://doi.org/10.1371/journal.pone.0221126.g002
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aVICs (natural-disease) compared to un-treated qVICs, with only one (MAMLD1) having the
opposite fold change, and the remaining 101 all up-regulated in both disease groups. Treat-
ment of aVICs with SB431542 reduced the gene signal intensity for TGFB1, 2 and 3, and this
was significant for TGFB3. TGFβ1 treatment of qVICs increased the expression of TGFB1, but
not TGFB2 or TGFB3. The full gene lists for these comparisons are shown in S3 to S7 Tables.
To interpret the transcriptomic data further, gene ontology (GO) terms and ingenuity path-
way analysis (IPA) was performed. These give insight into the roles that the differentially
expressed genes may be involved in. The top 10 GO terms for up- and down-regulated genes
for qVICs compared to aVICs were dominated by DNA replication, for qVICs treated with
TGFβ1 by extra cellular matrix regulation, for aVICs treated with SB431542 by mesenchymal
related terms, for TGFβ-treated qVICs compared to aVICs cell cycle and cell growth, and lastly
for the shared gene set for qVICs treated with TGFβ1 and aVICs by extracellular space and
smooth muscle proliferation. All the GO term comparisons are shown in S8 Table. IPA identi-
fied a number of canonical pathways significantly changed (p<0.05) in the different analyses
and the comparisons are listed as follows; 32, qVICs vs aVICs; 29, TGFβ1-qVICs vs qVICs; 37,
SB431542-aVICs vs aVICs; 25 TGFβ-treated qVICs vs aVICs; 44, TGFβ1-qVICs/aVICs vs
qVICs. The top three pathways for the five data sets are shown in Table 2.
Up-stream analysis identified an association of between 837 and 1034 up-stream regulators
for these comparisons. In both treatment data sets the top predicted up-stream regulator, not
Fig 3. Comparison of qVICs and aVICs. (A) Representative photomicrographs demonstrating morphology of normal (left image) and diseased (right image)
VICs. Scale bar = 100μM. (B) Representative protein immunoblotting illustrating αSMA expression in qVICs and aVICs cell cultures, and in response TGFβ1 (5ng/
ml) and/or SB431542 (10μM). (C) Mean cumulative TGFβ1 and 2 secretion after 120 hours for qVICs and aVICs (ELISA) (n = 3). Statistical analysis was performed
with Student’s t-test. � P<0.05.
https://doi.org/10.1371/journal.pone.0221126.g003
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surprisingly, was TGFβ1. The top up-stream regulators in untreated aVICs compared to
qVICs included proteins involved in cell cycle control and apoptosis (encoded by E2FA,
CDKN1A, TP53). Schematised illustrations of the networks are shown in S1 Fig. CDKN1A
and E2FA were also identified as the top two up-stream regulators when comparing TGFβ-
Fig 4. Pharmacological manipulation of αSMA expression. Protein immunoblotting illustrating: (A) Changes in αSMA expression in normal cells treated with
vehicle, 5ng/ml of TGFβ1 and 10μM of SB431542 (B) Abolition of αSMA expression in diseased cells by SB431542. (C) Reduction in αSMA expression in diseased
cells by treating with a pan anti-TGFβ antibody at 10μg/ml, but not by TGFβ specific antibodies. (D) Changes in deposition of proteoglycans (PG) in normal and
diseased cells in response to TGFβ1 and SB4341542. Statistical analysis was performed with Student’s t-test. �, ��, and ��� P<0.5, 0.1 and 0.01 respectively.
https://doi.org/10.1371/journal.pone.0221126.g004
Fig 5. Volcano plots comparing qVICs to aVICs and the effect of treatments on VICs. Red dots represent up-regulated genes, green represent genes that were
down-regulated and uncoloured are genes which do not pass the differential expression criteria. The X-axis shows fold change value and the Y-axis shows the P-
value. (A) Genes differentially expressed between qVICs + vehicle and qVICs treated with TGFβ1. (B) Genes differentially expressed between aVICs + vehicle and
aVICs treated with SB431542. (C) Differentially expressed genes between qVICs and aVICs. Statistical analysis was performed with paired or unpaired ANOVA.
https://doi.org/10.1371/journal.pone.0221126.g005
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treated with qVICs and aVICs. Although E2FA was predicted as the top up-stream regulator,
no predications could be made as to its effect on the data set. Overall there was inhibition of
the CDKN1A pathway. The shared up-stream regulators for aVICs and TGFβ1-treated qVICs
included TGFβ1 and TNF, with the former showing activation and the later slight inhibition.
Although transcripts for TNF and IFNG were identified in all data sets, no significant differ-
ences were found and signal intensity for the TGFBs was much higher (>2 orders of
magnitude).
Network analysis identified the prominent disease and function annotations for each of the
four comparison datasets and the top five are shown in S9 Table. Of particular note were func-
tions associated with cell cycle and movement, cardiovascular disease and developmental dis-
orders. Schematic representation of Cellular movement, cardiac arrhythmia and cardiovascular
disease; Cardiovascular disease, hereditary disorder, organismal injury and abnormalities; Cell
cycle, Cellular movement and cancer; Cell morphology, Cardiovascular disease and development
disorder are shown in S2 Fig.
Discussion
Phenotypic alteration of mitral valve VICs to activated myofibroblasts and EndoMT of VECs
are hallmarks of both canine and human myxomatous mitral valve disease [11, 22, 38, 39]. In
this study, we have demonstrated for the first time that retention of normal phenotype for
canine VICs (αSMA-) cultured from unaffected valves is possible using 2% FBS (DLF media),
as reported for human aortic valve VICs. These VICs did not undergo spontaneous activation
as in previous reports. Furthermore, aVICs from diseased valves under the DLF culture condi-
tions retained their activated myofibroblast phenotype (αSMA+). TGFβ1 could transform
qVICs to the disease aVIC phenotype, and this could be reversed using pan-anti-TGFβ anti-
bodies and the kinase inhibitor SB431542. The same effect was found in cells from diseased
valves, but 5HT or the 5HT2RB antagonist LY272015 had no effect. While exogenous TGFβ2
and 3 had similar effects as TGFβ1, the low level of secretion of TGFβ2 and 3 suggests that
Table 2. Canonical pathways.
Analysis Canonical Pathway Up Down Gene changes in pathway P-value
qVICs vs aVICs Cell cycle control of chromosomal replication 15 0 15/49 1.7E-09
Role of BRCA1 in DNA damage response 15 0 15/73 5.9E-07
Mitotic roles of polo-like kinase 12 1 12/60 1.7E-06
TGFβ1 treated qVICs vs qVICs Hepatic fibrosis/Hepatic stellate cell activation 6 4 10/160 0.00076
Integrin signaling 3 8 11/196 0.00102
Role of tissue factor in cancer 2 6 8/112 0.00107
SB431542 treated aVICs vs aVICs Superpathway of cholesterol biosynthesis 10 0 10/22 1E-12
Cholesterol biosynthesis I 0 7 7/11 13E-10
Cholesterol biosynthesis II 0 7 7/11 13E-10
TGFβ-treated qVICs vs aVICs Cell Cycle Control of Chromosomal Replication 19 0 19/49 1.58E-13
Mitotic Roles of Polo-Like Kinase 16 0 16/60 2.92E-08
Role of BRCA1 in DNA Damage Response 17 0 17/73 2.29E-08
Genes shared TGFβ1 treated qVICs and aVICs vs qVICs Superpathway of cholesterol biosynthesis 3 0 3/28 0.0002
Zymosterol biosynthesis 2 0 2/6 0.000025
Axonal guidance signaling 4 4 8/457 0.00059
Summary of top three canonical pathways associated with each dataset. The number of genes that were up- and down-regulated in the treated or activated cells in each
pathway as well as the total number of genes changed in each pathway is given. The P-value score gives the association of the gene list to the pathway.
https://doi.org/10.1371/journal.pone.0221126.t002
Cell culture myxomatous mitral valve disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0221126 August 15, 2019 10 / 18
TGFβ1 is the physiologically important isotype. We have also identified the transcriptomic dif-
ferences between normal and disease cells in culture and the effect of TGFβ1 and SB431542 on
gene expression. This is the first time that an effective reversal of induced- and naturally-
occurring disease phenotype has been achieved for MMVD, albeit under cell culture condi-
tions, and has implications for understanding pathogenesis and discovery of novel therapeutic
options applicable to MMVD.
Several molecular pathways have been identified as likely contributing to MMVD, the most
prominent being the TGFβ, 5HT and angiotensin pathways [14, 21, 30, 40, 41]. We examined
the effects of the latter two in our low serum culture model for VICs, but the effects were trivial
and we therefore decided to concentrate on TGFβ effects, with some additional studies of 5HT
in VICs. There are conflicting published data as to which of the TGFβ factors are most impor-
tant in human and canine MMVD, with some suggesting a single TGFβ factor or a combina-
tion of two [19, 21, 24, 42–44]. Determining if one or more TGFβ factors are implicated in
canine MMVD, and which one is then the major player, is necessary for selecting an inducer
of disease in any cell culture model. In this study, TGFβ1 was identified and selected as the
inducer of disease in vitro as it was the most abundant TGFβ secreted by cultured VICs and
was markedly increased in all diseased cells. We were able to induce some biological features
of MMVD in primary culture as early as 3 days. TGFβ1 induced dose-dependent activation of
VICs with up-regulation of αSMA, and these VICs had a myofibroblast aVIC morphology.
TGFβ1 stimulated VICs to increase proteoglycan deposition. In untreated VICs there were a
few αSMA positive cells whereas numbers rose in TGFβ1-treated cultures, which closely
resembles the situation in affected native valves [20, 21]. TGFβ1 also induced VEC EndoMT
with the endothelial cells differentiating into activated myofibroblasts. Addition of SB431542
or a pan-anti-TGFβ neutralising antibody was able to prevent or reverse myofibroblast differ-
entiation and EndoMT. TGFβ3 was barely detectable above baseline levels and can be excluded
from playing an important role in activation of VICs. These data suggest TGFβ1 as the main
driver of MMVD, with TGFβ2 possibly playing a secondary role. Overall, the ability to de-dif-
ferentiate aVICs from diseased valves to a qVIC phenotype and prevent further activation by
TGFβ1 is a novel and interesting finding.
In our culture system, both 5HT and LY272015 had no effect on normal and diseased VIC
phenotype. The up-regulation of the 5HTR2B and TAGLN by LY272015 is a recognised effect
of 5HT antagonists (inverse agonist) [45]. The potential role of 5HT in mitral valvulopathies
has been extensively reported, but a causative link has not been shown, apart from the rare
instances seen with carcinoid syndrome, appetite suppressants or anti-parkinsonian drugs
[30]. Gene profiling has identified up-regulation of 5HT receptor expression in both canine
and human mitral valvulopathies, but this appears to be an end-stage disease outcome [14, 16,
19, 31]. As shown here, TGFβ1 can induce 5HT2RB gene expression in qVICs, and 5HT2RB is
differentially expressed in diseased cells and expression was abolished by SB431542 in our cul-
ture system. Data presented here suggests 5HT has either no or only a minor role in VIC phe-
notype, and 5HT2RB receptor expression itself is controlled by TGFβ1 in cultured VICs [18,
31].
Proteoglycan deposition was shown to be affected by TGFβ1 in qVICs and inhibited by
SB431542 in aVICs, but there was no significant up-regulation of PG deposition in normal
VICs with exogenous TGFβ1. This might be due to absence of the modulatory effects of VECs
on ECM synthesis [5, 36].
The ability to inhibit and reverse EndoMT in normal cell cultures, or VIC activation in nor-
mal and diseased cell culture systems, indicates the potential utility of these cell culture systems
as early stage platforms for drug testing or discovery. The TGFβ pathway is a promising target
for therapeutic intervention if a system of delivery can be directed specifically to the mitral
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valves and to those targets that are MMVD exclusive. Further work is needed to examine the
down-steam signals and pathways that are TGFβ-dependent and contribute to the ECM
changes seen with MMVD. Our previous and ongoing transcriptomic profiling has also identi-
fied other pathways of potential interest, but TGFβ1 is still the prime up-stream regulator of
disease pathology, irrespective of stage of disease and severity score [14].
Expression of TNF and IFNγ, both at gene and protein level, was low to undetectable (by
ELISA) in the VIC populations. This indicates that autocrine VIC signalling of these factors is
unlikely. Circulating TNF and IFNγ have both previously been assessed in the dog and likewise
do not appear to be significantly altered in disease. However, paracrine signalling from VECs or
other potential valvular inflammatory cells cannot be ruled out [46, 47]. The mRNA expression
intensity for TGFβ2 and 3 approached that seen with TGFβ1, despite trivial protein expression
for both. This likely reflects differences in post-translational effects prior to secretion bound to
latent TGFβ binding proteins (LTBPs) [16]. Tissue immunohistochemistry has identified high
levels of expression of TGFβ1 and 3, but not TGFβ2, with only TGFβ1 found in the extra-cellu-
lar space, in canine MMVD valves [21]. The significantly higher level of TGFβ1 detected in
aVIC cultures compared to qVICs indicates its importance in MMVD [21, 23, 29, 48, 49].
Clear transcriptomic differences were identified with TGFβ1-treated qVICs showing the
greatest similarity to aVICs, and SB431542-treated aVICs showing similarity to qVICs. These
data demonstrate that a credible, though not complete, disease phenotype could be induced,
and that the disease phenotype could be transitioned closer to normal phenotype with treat-
ment. Additionally, a shared data set of 102 genes was found comparing induced
(TGFβ1-treated qVICs) and natural (aVICs) disease phenotypes. There was also a large un-
shared gene list comparing the two “disease” sets. Nevertheless, TGFβ1-treated qVICs did
show enhancement of GO terms recognised as hallmarks of MMVD, including extracellular
matrix and extracellular space, but also down-regulated positive regulation of ERK1/2, which
is not found in the natural disease state, and this may be due to negative feedback consequent
on pathway activation. [3, 23, 50, 51]. Treatment with SB431542 altered GO terms and gene
expression associated with the aVIC phenotype suggesting signaling through TGFβ RI is in-
part responsible for disease phenotype traits [52–54].
IPA identified Hepatic fibrosis/hepatic stellate cell activation as the main canonical pathway
in TGFβ1-treated qVICs, involving genes typically associated with aVICs in diseased tissue
[14]. Up-stream regulator analysis suggested activation of TGFβ1 signaling, with the effects of
SB431542 indicating this might involve TGFβ1–3, activin and nodal, but not BMPs [55, 56].
The down-regulation of genes associated with apoptotic pathways was an interesting finding
as it fits a narrative for the role of anti-apoptosis in MMVD and other chronic diseases, where
there is an increase in number and persistence of activated myofibroblasts, a condition that is
TGFβ1-dependent [22, 29, 53, 57]. Network analysis also identified disease and function bio-
logical terms, including cell morphology, cardiovascular disease and development disorder that
would be relevant to MMVD, where transition of qVICs to aVICs and initiation of EndoMT
are cardinal features of disease [3, 11, 12, 57].
Specific gene expression by RT-qPCR identified differential expression comparing qVICs
and aVICs, including typical markers of disease ACTA2, TAGLN, MYH10 and HTR2B [12, 14,
34]. Surprisingly, MYH10 expression was not affected by TGFβ1 or SB431542, suggesting con-
trol by another factor or delayed alteration under culture conditions. MYH10 encodes embry-
onic smooth muscle myosin, which is differentially expressed in aVICs from diseased valve
tissue, expressed alone or with αSMA [11, 34, 57]. While the potential role of 5HT in MMVD
has been previously reported, the regulation of the expression of HTR2B by TGFβ1 (up-) and
SB431542 (down-) suggests the proposed contribution of 5HT to MMVD pathogenesis is
likely to be TGFβ1-dependent [31].
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In order to optimise canine mitral valve cell cultures as credible disease model, further
work is needed to examine the regulation of signaling pathways, the relationship between the
VICs and VECs, the effects of endothelial trauma, mechanical strain and shear stress, and the
control of matrix-located latent-bound TGFβs release [34, 58].
Limitations
While sample size was sufficient to allow significant differences to be identified, larger samples
might have given more detailed insight into the changes seen. Sample size also needs to be con-
sidered given the problem of cell phenotype heterogeneity when sampling from a naturally
occurring diseased population. Confounding factors of age, disease severity, and, in the case of
the dog, breed, also need to be considered. However, it can be argued that the data presented
here represent a more complete cross-section of the population than if a single breed had been
examined, and are therefore more representative of disease phenotype. The difficulty in har-
vesting and culturing sufficient VECs from diseased valves was disappointing as modelling
MMVD will require examination of those cells and how they interact with stromal VICs, and
further work is needed in this area. Further work is also needed to examine changes in specific
ECM components such as collagens, elastin and proteoglycans in these culture systems. Lastly,
while this 2D monoculture does give some insight into the patho-biology of MMVD, more
complex 3D single cell and co-cultures would allow more detailed modelling of both the nor-
mal and diseased valve.
Conclusion
We have shown it is feasible to induce, in a TGFβ1 concentration-dependent manner,
EndoMT and activated myofibroblast phenotype in normal canine VECs and VICs respec-
tively, and to reverse naturally-occurring disease phenotype in canine mitral valve VICs. We
identified TGFβ1 as the main driver of disease phenotype, and that inhibition of TGFβ can
completely inhibit VIC activation. We did not identify any significant contribution of 5HT,
but our data indicate that any changes in 5HT signalling were likely to be TGFβ1-mediated.
Simple cell culture systems, using a low serum protocol, can partially model MMVD and more
sophisticated culture methods can now be developed to achieve greater approximation to the
gene and protein changes seen in disease.
Supporting information
S1 Table. Details of antibodies used. IF, immunofluorescence and protein; WB Western pro-
tein immuno-blotting; VIC, valve interstitial cell; VEC, valve endothelial cell; EndoMT, endo-
thelial-to-mesenchymal transition.
(PDF)
S2 Table. RT-qPCR validation of microarray data. A. Microarray data for selected genes. B.
RT-qPCR data for the same selected genes. Differences are shown for 5HTR2B and BMPER
highlighted in yellow for aVIC/qVIC dataset comparison.
(PDF)
S3 Table. Gene list qVICs vs aVICs with fold change < or > 1.5 (902 differentially
expressed genes; 406 down 496 up).
(PDF)
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S4 Table. Gene list TGFβ1-treated qVICs vs qVICs with fold change < or > 1.5 (275 differ-
entially expressed genes; 144 down, 131 up).
(PDF)
S5 Table. Gene list SB431542 treated aVICs vs aVICs with fold change < or > 1.5 (236 dif-
ferentially expressed genes; 115 down, 121 up).
(PDF)
S6 Table. Gene list TGFβ1-treated qVICs vs aVICs with fold change < or > 1.5 (832 differ-
entially expressed genes; 490 down, 342 up).
(PDF)
S7 Table. 102 shared differentially expressed genes in the TGFβ1-treated qVICs and aVICs
datasets compared to un-treated qVICs. All gene showed the same direction of change
(down) except for MALD1.
(PDF)
S8 Table. Top 10 up and down regulated GO terms for different data set comparisons. A.
qVICs/aVICs; B. TGFβ1-qVICs/qVICs; C. SB431542-aVICs/aVICs; D. TGFβ1-qVICs/aVICs;
E. shared gene set for TGFB1-treated qVICs and aVICs.
(PDF)
S9 Table. Disease and function annotations. Top five disease and function networks associ-
ated with the genes differentially expressed between A TGFβ1-qVICs/qVICs; B SB431542-a-
VICs/aVICs; C qVICs/aVICs; D TGFβ1-qVICs/aVICs. Underlined networks are shown
schematically below.
(PDF)
S1 Fig. Gene networks and up-stream regulators (A-E). Networks of genes differentially
expressed showing downstream effects from the extracellular space to the nucleus. Genes are col-
oured red and green to represent up- or down-regulation in the dataset. Dotted lines connecting
the regulator to these genes show the expected effect of regulator signalling: orange—activation,
blue—inhibition, yellow—result inconsistent and grey—effect not predicted. A. TGFβ1 network;
TGFβ1-qVICs/qVICs; B. TGFβ1 network; SB431542-aVICs/aVICs; C. E2F4 network; aVICs/
qVICs; D. CDKN1A network; aVICs/qVICs; E.TGFβ1 network; aVICs/TGFβ1-qVICs/.
(TIF)
S2 Fig. Schematic representations of disease and function networks highlighted in S7
Table. Genes are shown in their protein cellular location with red indicating up-regulation,
green down-regulation and un-coloured showing no change in the dataset. A. Cellular move-
ment, cardiac arrhythmia and cardiovascular disease; B. Cardiovascular disease, hereditary dis-
order, organismal injury and abnormalities; C. Cell cycle, cellular movement and Cancer; D.
Cell morphology, cardiovascular disease and development disorder.
(TIF)
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